Fellow investors, once again, we the common shareholders of a publicly owned but seemingly privately run Keryx Biopharmaceuticals, have to find out about important developments with our company via our own due diligence.
As was the case with VP of Sales (Tony Chambers) departure thru Cafepharma....or Keryx’s wide organizational structure of 210 headcount thru zoominfo.com......or photos of expanded 27,300 sq. ft. offices with multimillion renovations thru glassdoor.com.....or Helen Milton PdD, VP Global Regulatory Affairs at Keryx Sept. 2014-May 2017 (Auryxia CKD/IDA Auryxia), then switching to AMAG, VP Regulatory Affairs June 2017-Present (Feraheme IDA)..... ..or Fexeric groundwork in Europe label/packaging/package leaflet thru Rxed.eu and ema.eurpopa.eu.......or recent National Sales Meeting in Miami thru Cafe Pharma.. and now Keryx receiving an Innovative Award for IDA thru National Kidney Flundation.
It seems the company has had no interest in keeping shareholders informed, on the contrary, it seems it has made a concerted effort to keep shareholders in the dark. Again, a publicly owned company run like a private company, IMO.
Finally, IMO, not clear on IR seeming to want to communicate thru some anonymous poster on a public message board. Two (2) rounds of talks yet, as per anonymous poster Yoshka’s/gwells’ reports from such talks, IMO, talks reflect some versions of “comic screenplays”.
What gives with these people, seriously????
ALL IMO
AI
